Citation Impact
Citing Papers
Improved antitumor activity of immunotherapy with BRAF and MEK inhibitors in BRAF V600E melanoma
2015
Preoperative CTLA-4 Blockade: Tolerability and Immune Monitoring in the Setting of a Presurgical Clinical Trial
2010 StandoutNobel
Talimogene Laherparepvec in Combination With Ipilimumab in Previously Untreated, Unresectable Stage IIIB-IV Melanoma
2016
PD-L1-deficient mice show that PD-L1 on T cells, antigen-presenting cells, and host tissues negatively regulates T cells
2004
CSF1/CSF1R Blockade Reprograms Tumor-Infiltrating Macrophages and Improves Response to T-cell Checkpoint Immunotherapy in Pancreatic Cancer Models
2014
TGFβ Is a Master Regulator of Radiation Therapy-Induced Antitumor Immunity
2015
Inhibition of CD47 Effectively Targets Pancreatic Cancer Stem Cells via Dual Mechanisms
2015
Nivolumab for Metastatic Renal Cell Carcinoma: Results of a Randomized Phase II Trial
2014
PD-1 Blunts the Function of Ovarian Tumor–Infiltrating Dendritic Cells by Inactivating NF-κB
2015
Commensal Bifidobacterium promotes antitumor immunity and facilitates anti–PD-L1 efficacy
2015 StandoutScience
Genetic Evolution of T-cell Resistance in the Course of Melanoma Progression
2014
Systematic Functional Characterization of Resistance to PI3K Inhibition in Breast Cancer
2016
TWIST1-Induced miR-424 Reversibly Drives Mesenchymal Programming while Inhibiting Tumor Initiation
2015
Programmed cell death 1 ligand 1 and tumor-infiltrating CD8 + T lymphocytes are prognostic factors of human ovarian cancer
2007 StandoutNobel
PhyloWGS: Reconstructing subclonal composition and evolution from whole-genome sequencing of tumors
2015
Hyperprogressors after Immunotherapy: Analysis of Genomic Alterations Associated with Accelerated Growth Rate
2017
Regulated Expression of a Tumor-Associated Antigen Reveals Multiple Levels of T-Cell Tolerance in a Mouse Model of Lung Cancer
2008
VISTA Regulates the Development of Protective Antitumor Immunity
2014
A Phase I Trial of BKM120 (Buparlisib) in Combination with Fulvestrant in Postmenopausal Women with Estrogen Receptor–Positive Metastatic Breast Cancer
2015
Early Adaptation and Acquired Resistance to CDK4/6 Inhibition in Estrogen Receptor–Positive Breast Cancer
2016
Insulin-induced remission in new-onset NOD mice is maintained by the PD-1–PD-L1 pathway
2006
PD-1 + regulatory T cells amplified by PD-1 blockade promote hyperprogression of cancer
2019 StandoutNobel
2015 American Thyroid Association Management Guidelines for Adult Patients with Thyroid Nodules and Differentiated Thyroid Cancer: The American Thyroid Association Guidelines Task Force on Thyroid Nodules and Differentiated Thyroid Cancer
2015 Standout
Adoptive T-Cell Therapy for Cancer
2016
A prospective phase II trial exploring the association between tumor microenvironment biomarkers and clinical activity of ipilimumab in advanced melanoma
2011
PD-1 expression by tumour-associated macrophages inhibits phagocytosis and tumour immunity
2017 StandoutNature
Hallmarks of Cancer: The Next Generation
2011 Standout
Exploiting CTLA-4, PD-1 and PD-L1 to reactivate the host immune response against cancer
2013
PD-1/PD-L pathway inhibits M.tb-specific CD4+ T-cell functions and phagocytosis of macrophages in active tuberculosis
2016
Phase II Study of Taselisib (GDC-0032) in Combination with Fulvestrant in Patients with HER2-Negative, Hormone Receptor–Positive Advanced Breast Cancer
2018
Pan-cancer patterns of somatic copy number alteration
2013
Cancer type‐dependent genetic interactions between cancer driver alterations indicate plasticity of epistasis across cell types
2015
A Novel Antagonist of the Immune Checkpoint Protein Adenosine A2a Receptor Restores Tumor-Infiltrating Lymphocyte Activity in the Context of the Tumor Microenvironment
2017
Cancer immunotherapy: the beginning of the end of cancer?
2016
A network modeling approach to elucidate drug resistance mechanisms and predict combinatorial drug treatments in breast cancer
2017
Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries
2021 Standout
Circulating Tumor Cell Clusters Are Oligoclonal Precursors of Breast Cancer Metastasis
2014 Standout
Phase I Study of Single-Agent Anti–Programmed Death-1 (MDX-1106) in Refractory Solid Tumors: Safety, Clinical Activity, Pharmacodynamics, and Immunologic Correlates
2010 Standout
Pembrolizumab as Second-Line Therapy for Advanced Urothelial Carcinoma
2017 Standout
Nivolumab monotherapy in recurrent metastatic urothelial carcinoma (CheckMate 032): a multicentre, open-label, two-stage, multi-arm, phase 1/2 trial
2016
Systemic Immunity Is Required for Effective Cancer Immunotherapy
2017
Augmenting Antitumor Immune Responses with Epigenetic Modifying Agents
2015
Elements of cancer immunity and the cancer–immune set point
2017 StandoutNature
A view on drug resistance in cancer
2019 StandoutNature
Long term survival with cytotoxic T lymphocyte-associated antigen 4 blockade using tremelimumab
2015
BRCAness revisited
2016
Combining immunotherapy and targeted therapies in cancer treatment
2012
Nivolumab plus ipilimumab as first-line treatment for advanced non-small-cell lung cancer (CheckMate 012): results of an open-label, phase 1, multicohort study
2016
Evolution of the cancer genome
2012
The biology and management of non-small cell lung cancer
2018 StandoutNature
Mechanism of tumor rejection with doublets of CTLA-4, PD-1/PD-L1, or IDO blockade involves restored IL-2 production and proliferation of CD8+ T cells directly within the tumor microenvironment
2014
Spatial and Temporal Heterogeneity in High-Grade Serous Ovarian Cancer: A Phylogenetic Analysis
2015
Integrating liquid biopsies into the management of cancer
2017
Immune Checkpoints as Therapeutic Targets in Autoimmunity
2018
PDL1 Regulation by p53 via miR-34
2015
Clonal Heterogeneity and Tumor Evolution: Past, Present, and the Future
2017 Standout
Predictive factors for hyperprogressive disease during nivolumab as anti-PD1 treatment in patients with advanced gastric cancer
2019
Origins of Metastatic Traits
2013
Adoptive T Cell Therapies: A Comparison of T Cell Receptors and Chimeric Antigen Receptors
2015
Functional Genomic Landscape of Human Breast Cancer Drivers, Vulnerabilities, and Resistance
2016
Metastatic Stem Cells: Sources, Niches, and Vital Pathways
2014
STING-Dependent Cytosolic DNA Sensing Mediates Innate Immune Recognition of Immunogenic Tumors
2014
Control of the Immune Response by Pro-Angiogenic Factors
2014
Blockade of adenosine A2A receptor enhances CD8+ T cells response and decreases regulatory T cells in head and neck squamous cell carcinoma
2017
Interdependent IL-7 and IFN-γ signalling in T-cell controls tumour eradication by combined α-CTLA-4+α-PD-1 therapy
2016 StandoutNobel
Metastatic spread in patients with non-small cell lung cancer is associated with a reduced density of tumor-infiltrating T cells
2015
Identification of Druggable Cancer Driver Genes Amplified across TCGA Datasets
2014
Tumor Interferon Signaling Regulates a Multigenic Resistance Program to Immune Checkpoint Blockade
2016
Plasticity of disseminating cancer cells in patients with epithelial malignancies
2012
Cancer immunoediting from immune surveillance to immune escape
2007
MPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancer
2014 StandoutNature
Spatial intratumoral heterogeneity and temporal clonal evolution in esophageal squamous cell carcinoma
2016
Molecular and Genetic Properties of Tumors Associated with Local Immune Cytolytic Activity
2015 Standout
Evolving synergistic combinations of targeted immunotherapies to combat cancer
2015
Tumor metastasis: moving new biological insights into the clinic
2013
Feedback Suppression of PI3Kα Signaling in PTEN-Mutated Tumors Is Relieved by Selective Inhibition of PI3Kβ
2014
CRISPR-Barcoding for Intratumor Genetic Heterogeneity Modeling and Functional Analysis of Oncogenic Driver Mutations
2016
Engineered T cells: the promise and challenges of cancer immunotherapy
2016
Implications of the Hybrid Epithelial/Mesenchymal Phenotype in Metastasis
2015
The Cancer Stem Cell Niche: How Essential Is the Niche in Regulating Stemness of Tumor Cells?
2015
The hypoxic tumor microenvironment: A driving force for breast cancer progression
2015 StandoutNobel
Structure of the Complex of Human Programmed Death 1, PD-1, and Its Ligand PD-L1
2015
Immune Checkpoint Targeting in Cancer Therapy: Toward Combination Strategies with Curative Potential
2015 StandoutNobel
SciClone: Inferring Clonal Architecture and Tracking the Spatial and Temporal Patterns of Tumor Evolution
2014
The Next Hurdle in Cancer Immunotherapy: Overcoming the Non–T-Cell–Inflamed Tumor Microenvironment
2015
Novel cancer immunotherapy agents with survival benefit: recent successes and next steps
2011 StandoutNobel
Intratumoral Heterogeneity of the Epigenome
2016
PD-1 marks dysfunctional regulatory T cells in malignant gliomas
2016
Combined immune checkpoint blockade as a therapeutic strategy for BRCA1 -mutated breast cancer
2017
Development of immuno-oncology drugs — from CTLA4 to PD1 to the next generations
2016
Frequencies of circulating MDSC correlate with clinical outcome of melanoma patients treated with ipilimumab
2013
Tumour heterogeneity and cancer cell plasticity
2013 StandoutNature
Evaluation of Factors Related to Late Recurrence - Later than 10 Years after the Initial Treatment - in Primary Breast Cancer
2013 Standout
The PD‐1 pathway in tolerance and autoimmunity
2010 Standout
Stemness of the hybrid Epithelial/Mesenchymal State in Breast Cancer and Its Association with Poor Survival
2015
Molecular mechanisms of T cell co-stimulation and co-inhibition
2013 Standout
Emerging Biological Principles of Metastasis
2017 Standout
Metabolic Competition in the Tumor Microenvironment Is a Driver of Cancer Progression
2015 Standout
Targeting metastasis-initiating cells through the fatty acid receptor CD36
2016 Nature
Primary, Adaptive, and Acquired Resistance to Cancer Immunotherapy
2017 Standout
EMT: 2016
2016 Standout
Cessation of CCL2 inhibition accelerates breast cancer metastasis by promoting angiogenesis
2014 Nature
Interferon Receptor Signaling Pathways Regulating PD-L1 and PD-L2 Expression
2017
The causes and consequences of genetic heterogeneity in cancer evolution
2013 StandoutNature
Lag-3, Tim-3, and TIGIT: Co-inhibitory Receptors with Specialized Functions in Immune Regulation
2016 Standout
Punctuated copy number evolution and clonal stasis in triple-negative breast cancer
2016
The blockade of immune checkpoints in cancer immunotherapy
2012 Standout
Combination immunotherapy with α-CTLA-4 and α-PD-L1 antibody blockade prevents immune escape and leads to complete control of metastatic osteosarcoma
2015
Cancer immunotherapy — immune checkpoint blockade and associated endocrinopathies
2017
Intestinal microbiome analyses identify melanoma patients at risk for checkpoint-blockade-induced colitis
2016
Melanoma-intrinsic β-catenin signalling prevents anti-tumour immunity
2015 StandoutNature
The future of cancer treatment: immunomodulation, CARs and combination immunotherapy
2016
PyClone: statistical inference of clonal population structure in cancer
2014
Melanoma brain metastases treated with stereotactic radiosurgery and concurrent pembrolizumab display marked regression; efficacy and safety of combined treatment
2017
Driving CAR T-cells forward
2016
Enhancing Cancer Immunotherapy Via Activation of Innate Immunity
2015
Programmed death ligand 1 expression and tumor-infiltrating lymphocytes in glioblastoma
2014
Immune cell promotion of metastasis
2015
Distinct Cellular Mechanisms Underlie Anti-CTLA-4 and Anti-PD-1 Checkpoint Blockade
2017 StandoutNobel
The PI3K Pathway in Human Disease
2017 Standout
Integrating Proteomics and Transcriptomics for Systematic Combinatorial Chimeric Antigen Receptor Therapy of AML
2017
T-Cell Transfer Therapy Targeting Mutant KRAS in Cancer
2016
Macrophages and Therapeutic Resistance in Cancer
2015
Mutant MHC class II epitopes drive therapeutic immune responses to cancer
2015 Nature
Susceptibility genes in the pathogenesis of murine lupus.
2002
Review of immune-related adverse events in prostate cancer patients treated with ipilimumab: MD Anderson experience
2015
Monitoring immune responses in the tumor microenvironment
2016
SGK3 Mediates INPP4B-Dependent PI3K Signaling in Breast Cancer
2014
Combinatorial Strategies for the Induction of Immunogenic Cell Death
2015
A neoantigen fitness model predicts tumour response to checkpoint blockade immunotherapy
2017 Nature
Innate immune signaling and regulation in cancer immunotherapy
2016
Microenvironmental Heterogeneity Parallels Breast Cancer Progression: A Histology–Genomic Integration Analysis
2016
Immune Checkpoint Blockade: A Common Denominator Approach to Cancer Therapy
2015 Standout
The prognostic landscape of genes and infiltrating immune cells across human cancers
2015 Standout
CD25<sup>+</sup>CD4<sup>+</sup> Regulatory T-Cells in Cancer
2005
Therapeutic T cell engineering
2017 Nature
Combination immunotherapy: a road map
2017
Metabolic Regulation of T Cell Longevity and Function in Tumor Immunotherapy
2017
Macrophage IL-10 Blocks CD8+ T Cell-Dependent Responses to Chemotherapy by Suppressing IL-12 Expression in Intratumoral Dendritic Cells
2014
Targeting T cell metabolism for therapy
2015
The phosphoinositide 3-kinase pathway and therapy resistance in cancer
2015
Dabrafenib plus trametinib in patients with previously treated BRAFV600E-mutant metastatic non-small cell lung cancer: an open-label, multicentre phase 2 trial
2016
Computational design of a synthetic PD-1 agonist
2021 StandoutNobel
Introduction to checkpoint inhibitors and cancer immunotherapy
2017
Establishment of NOD-Pdcd1-/-mice as an efficient animal model of type I diabetes
2005 StandoutNobel
NF-κB Regulates PD-1 Expression in Macrophages
2015
Clonal status of actionable driver events and the timing of mutational processes in cancer evolution
2015
Pooled Analysis of Long-Term Survival Data From Phase II and Phase III Trials of Ipilimumab in Unresectable or Metastatic Melanoma
2015 Standout
PD-1 Inhibits Antiviral Immunity at the Effector Phase in the Liver
2003 StandoutNobel
The landscape of metastatic progression patterns across major human cancers
2014
Tumor immune escape mechanisms: impact of the neuroendocrine system
2006
Phosphoproteomic Analysis Identifies Grb10 as an mTORC1 Substrate That Negatively Regulates Insulin Signaling
2011 Science
Combination Therapy with Anti–CTLA-4 and Anti–PD-1 Leads to Distinct Immunologic Changes In Vivo
2014
Adoptive cell transfer as personalized immunotherapy for human cancer
2015 StandoutScience
Facilitation of β Selection and Modification of Positive Selection in the Thymus of Pd-1–Deficient Mice
2000 StandoutNobel
Nonoverlapping roles of PD-1 and FoxP3 in maintaining immune tolerance in a novel autoimmune pancreatitis mouse model
2016 StandoutNobel
Cdk5 disruption attenuates tumor PD-L1 expression and promotes antitumor immunity
2016 Science
Expression and regulation of the PD-L1 immunoinhibitory molecule on microvascular endothelial cells.
2002
The DNA cytosine deaminase APOBEC3B promotes tamoxifen resistance in ER-positive breast cancer
2016
Tumor Exome Analysis Reveals Neoantigen-Specific T-Cell Reactivity in an Ipilimumab-Responsive Melanoma
2013
Targeting ALK: Precision Medicine Takes on Drug Resistance
2017
SDPR functions as a metastasis suppressor in breast cancer by promoting apoptosis
2016
Immunological mechanisms of the antitumor effects of supplemental oxygenation
2015
Engineering high-affinity PD-1 variants for optimized immunotherapy and immuno-PET imaging
2015
The efficacy and potential predictive factors of PD-1/PD-L1 blockades in epithelial carcinoma patients: a systematic review and meta analysis
2016
Hypoxia-inducible factor 1-dependent expression of adenosine receptor 2B promotes breast cancer stem cell enrichment
2018 StandoutNobel
The PD-1/PD-L1 complex resembles the antigen-binding Fv domains of antibodies and T cell receptors
2008 StandoutNobel
Characterization of tumor infiltrating lymphocytes in paired primary and metastatic renal cell carcinoma specimens
2015
Safety and Efficacy of Durvalumab (MEDI4736), an Anti–Programmed Cell Death Ligand-1 Immune Checkpoint Inhibitor, in Patients With Advanced Urothelial Bladder Cancer
2016
IL-27 gene therapy induces depletion of Tregs and enhances the efficacy of cancer immunotherapy
2018
The epigenetic landscape of T cell exhaustion
2016 Science
Molecular Modeling and Functional Mapping of B7-H1 and B7-DC Uncouple Costimulatory Function from PD-1 Interaction
2003 StandoutNobel
PD-L1 (B7-H1) and PD-1 pathway blockade for cancer therapy: Mechanisms, response biomarkers, and combinations
2016 Standout
Chemotherapy induces enrichment of CD47 + /CD73 + /PDL1 + immune evasive triple-negative breast cancer cells
2018 StandoutNobel
The Role of Tumoral FOXP3 on Cell Proliferation, Migration, and Invasion in Gastric Cancer
2017 Standout
The commensal microbiome is associated with anti–PD-1 efficacy in metastatic melanoma patients
2018 StandoutScience
Chimeric Antigen Receptor Therapy
2018 Standout
PD-L1 and PD-L2 are differentially regulated by Th1 and Th2 cells
2003 StandoutNobel
Unique potential of 4-1BB agonist antibody to promote durable regression of HPV + tumors when combined with an E6/E7 peptide vaccine
2015 StandoutNobel
Intratumor Heterogeneity: Evolution through Space and Time
2012
Regulatory T Cells in the Tumor Microenvironment and Cancer Progression: Role and Therapeutic Targeting
2016
Metabolic reprogramming and cancer progression
2020 StandoutScience
FDA Approval Summary: Nivolumab for the Treatment of Metastatic Non-Small Cell Lung Cancer With Progression On or After Platinum-Based Chemotherapy
2016
The efficacy and safety of anti-PD-1/PD-L1 antibodies for treatment of advanced or refractory cancers: a meta-analysis
2016
Cancer Genome Landscapes
2013 StandoutScience
Precision glycocalyx editing as a strategy for cancer immunotherapy
2016 StandoutNobel
PD-1 immunoreceptor inhibits B cell receptor-mediated signaling by recruiting src homology 2-domain-containing tyrosine phosphatase 2 to phosphotyrosine
2001 StandoutNobel
OX40, PD‐1 and CTLA‐4 are selectively expressed on tumor‐infiltrating T cells in head and neck cancer
2016
Clonal expansion of CD8 T cells in the systemic circulation precedes development of ipilimumab-induced toxicities
2016 StandoutNobel
Blood-Based Analyses of Cancer: Circulating Tumor Cells and Circulating Tumor DNA
2014
Neoantigen landscape dynamics during human melanoma–T cell interactions
2016 Nature
Proliferation of PD-1+ CD8 T cells in peripheral blood after PD-1–targeted therapy in lung cancer patients
2017
Anti–PD-1/PD-L1 therapy of human cancer: past, present, and future
2015
Carboplatin and pemetrexed with or without pembrolizumab for advanced, non-squamous non-small-cell lung cancer: a randomised, phase 2 cohort of the open-label KEYNOTE-021 study
2016
IFN-γ–related mRNA profile predicts clinical response to PD-1 blockade
2017 Standout
Analysis of ESR1 mutation in circulating tumor DNA demonstrates evolution during therapy for metastatic breast cancer
2015
The Programmed Death-1 (PD-1) Pathway Regulates Autoimmune Diabetes in Nonobese Diabetic (NOD) Mice
2003
PD-1 Blockade with Nivolumab in Relapsed or Refractory Hodgkin's Lymphoma
2014 Standout
HIF-1 regulates CD47 expression in breast cancer cells to promote evasion of phagocytosis and maintenance of cancer stem cells
2015 StandoutNobel
Targeting CXCL12 from FAP-expressing carcinoma-associated fibroblasts synergizes with anti–PD-L1 immunotherapy in pancreatic cancer
2013
Adaptive Immune Resistance: How Cancer Protects from Immune Attack
2015
Chemotherapy triggers HIF-1–dependent glutathione synthesis and copper chelation that induces the breast cancer stem cell phenotype
2015 StandoutNobel
Therapeutic cancer vaccines
2015
Detailed characterization of tumor infiltrating lymphocytes in two distinct human solid malignancies show phenotypic similarities
2014
Systemic Therapy for Stage IV Non–Small-Cell Lung Cancer: American Society of Clinical Oncology Clinical Practice Guideline Update
2015
Immune Checkpoint Blockade in Cancer Therapy
2015 Standout
PI3K pathway regulates ER-dependent transcription in breast cancer through the epigenetic regulator KMT2D
2017 Science
Cancer immunotherapy using checkpoint blockade
2018 StandoutScience
PD-1 and Its Ligands in Tolerance and Immunity
2008 Standout
Involvement of PD-L1 on tumor cells in the escape from host immune system and tumor immunotherapy by PD-L1 blockade
2002 StandoutNobel
N‐Carboxyanhydride Polymerization of Glycopolypeptides That Activate Antigen‐Presenting Cells through Dectin‐1 and Dectin‐2
2018 StandoutNobel
Ipilimumab-dependent cell-mediated cytotoxicity of regulatory T cells ex vivo by nonclassical monocytes in melanoma patients
2015
Tumor immune profiling predicts response to anti–PD-1 therapy in human melanoma
2016
Works of Markus Wallwiener being referenced
Bone marrow versus sentinel lymph node involvement in breast cancer: a comparison of early hematogenous and early lymphatic tumor spread
2011
Identification of a population of blood circulating tumor cells from breast cancer patients that initiates metastasis in a xenograft assay
2013
PD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer
2016 Standout
Tumor cell dissemination to the bone marrow and blood is associated with poor outcome in patients with metastatic breast cancer
2014
Co-expression of MET and CD47 is a novel prognosticator for survival of luminal-type breast cancer patients
2014